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Abstract
Background: Maturity‐onset diabetes of the young (MODY) is a form of monogenic 
diabetes with autosomal dominant inheritance. To date, mutations in 11 genes have 
been frequently associated with this phenotype. In Brazil, few cohorts have been 
screened for MODY, all using a candidate gene approach, with a high prevalence of 
undiagnosed cases (MODY-X).
Methods: We conducted a next‐generation sequencing target panel (tNGS) study to 
investigate, for the first time, a Brazilian cohort of MODY patients with a negative 
prior genetic analysis. One hundred and two patients were selected, of which 26 had 
an initial clinical suspicion of MODY‐GCK and 76 were non‐GCK MODY.
Results: After excluding all benign and likely benign variants and variants of uncertain sig-
nificance, we were able to assign a genetic cause for 12.7% (13/102) of the probands. Three 
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1 |  INTRODUCTION
Maturity‐onset diabetes of the young (MODY) (OMIM 
#606391) is characterized by defects in insulin secretion, au-
tosomal dominant inheritance, early hyperglycemia onset, and 
negative anti‐beta cell antibodies (Fajans & Bell, 2011; Fajans, 
Bell, & Polonsky, 2001; McDonald et al., 2011; Vaxillaire & 
Froguel, 2008). To date, mutations in 11 genes have been fre-
quently associated with MODY, some of which have recently 
been described (Bonnefond et al., 2012; Bowman et al., 2012; 
Prudente et al., 2015). Few cases, however, have been associ-
ated with the KLF11, PAX4, and BLK, and the validity of their 
association with the MODY phenotype is currently questioned 
(Flannick et al., 2013; Sanyoura, Philipson, & Naylor, 2018). 
Definitive diagnosis relies on genetic tests, traditionally by 
Sanger sequencing (Sanger & Coulson, 1975). However, given 
the genetic heterogeneity of this condition and the difficulty 
related to studying some genes due to their large size or lack of 
hotspots, next‐generation sequencing (NGS) seems promising 
for a cost‐effective genetic analysis upon clinical suspicion of 
MODY (American Diabetes Association, 2017; Colclough, 
Saint‐Martin, Timsit, Ellard, & Bellanné‐Chantelot, 2014). In 
Brazil, few cohorts have been screened for MODY, and all of 
them have been conducted using a candidate gene approach 
(mainly GCK/HNF1A) with a high prevalence of MODY-X 
(unclear genetic diagnosis—46.2%–73.9%) (Furuzawa et al., 
2008; Giuffrida et al., 2017; Maraschin et al., 2008; Moises 
et al., 2001; Santana et al., 2017), which could be explained 
by genes that are more rarely associated with MODY. The 
objective of this study was to use an NGS target panel (tNGS) 
to investigate a Brazilian cohort of MODY patients with nega-
tive prior genetic analysis by Sanger sequencing or Multiplex 
ligation ‐dependent probe amplification (MLPA).
2 |  MATERIALS AND METHODS
2.1 | Subjects
Starting with a single‐gene approach previously published 
(Dotto et al., 2019; Santana et al., 2017) for three MODY 
subtypes: GCK (MODY‐GCK) (OMIM #125851) or HNF1A 
(OMIM #600496)/HNF1B (OMIM #137920) (MODY non‐
GCK) (Figure 1 and supplemental material, cohort selection 
and data analysis), 102 patients with negative prior genetic 
analysis were selected for this targeted NGS study.
All the subjects were referred to the Monogenic Diabetes 
Group, School of Medicine, University of Sao Paulo (USP) 
using electronic forms (available at www.diabe tesge netic 
ousp.com) or directly by the medical centers or universities 
from all regions of Brazil. The patients and/or legal guardians 
provided written informed consent.
2.2 | Library preparation and sequencing
Samples from the 102 selected patients were subjected to 
genomic quality and integrity control (Bioanalyzer, Agilent 
Technologies) as well as DNA shearing (Covaris) prior to the 
enrichment protocol. The full region (upstream, exons, and 
introns) of 11 previously described genes frequently associ-
ated with MODY (HNF4A, GCK, HNF1A, PDX1, HNF1B, 
NEUROD1, CEL, INS, ABCC8, KCNJ11, and APPL1) was cap-
tured and enriched using a custom genetic panel (SureSelect XT, 
Agilent Technologies). Paired‐end sequencing was performed 
in a sequencing‐by‐synthesis assay (MiSeq System, Illumina). 
The manufacturer's instructions were followed in all steps.
2.3 | Bioinformatics analysis
Each step performed and the programs used during pre-
liminary processing, genomic mapping, variant calling, and 
annotation of the sequencing data are detailed in the supple-
mental material—cohort selection and data analysis.
2.4 | Variant filtering workflow and 
pathogenicity interpretation
A prioritization process was applied to reduce the list of can-
didate variants for association with MODY. The allele fre-
quency was evaluated using a public consortium and a local 
genomic database, namely, gnomAD (Lek et al., 2016) and 
ABraOM (Naslavsky et al., 2017), respectively. In addition 
Technological Development (CNPq) grant 
#160044/2013‐8 awarded to RPD. rare MODY subtypes were identified (PDX1/NEUROD1/ABCC8), and eight variants had 
not been previously described/mapped in genomic databases. Important clinical findings 
were evidenced in some cases after genetic diagnosis, such as MODY‐PDX1/HNF1B.
Conclusion: A multiloci genetic approach allowed the identification of rare MODY 
subtypes, reducing the large percentage of MODY-X in Brazilian cases and contributing 
to a better clinical, therapeutic, and prognostic characterization of these rare phenotypes.
K E Y W O R D S
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to minor allele frequency < 1%, each final candidate variant 
was evaluated in relation to the MODY estimated frequency 
(0.01%) (Shields et al., 2010). This step was performed later 
to avoid exclusion of variants with border frequency in the 
initial filtering process. We interpreted the pathogenicity of 
each candidate variant according to the British Society for 
Genetic Medicine recommendations (Wallis et al., 2013) and 
the American College of Medical Genetics and Genomics 
(ACMG)/Association for Molecular Pathology (AMP) guide- 
lines (Richards et al., 2015). To support familial cosegrega-
tion analysis, a mathematical model (Jarvik & Browning, 
2016) was added to the ACMG/AMP ranking, allowing for 
the statistical quantification of familial aggregation data.
The location of each candidate variant was verified in 
the patients' binary alignment map file (BAM) using the 
Integrative Genomics Viewer (IGV) (Robinson et al., 2011). 
Sanger sequencing was performed as a confirmatory method. 
The details of the filtering workflow and pathogenicity inter-
pretation are presented in the supplemental materials—co-
hort selection and data analysis.
3 |  RESULTS
3.1 | Subjects
One hundred and two patients with a negative prior genetic 
analysis were selected for target NGS. Twenty‐six of these 
had an initial clinical suspicion of MODY‐GCK and 76 of 
non‐GCK MODY. The cohort was composed of 37.3% 
males. The clinical and laboratory data at the first evaluation 
are presented in Table 1.
3.2 | Sequencing metrics
Table S1 summarizes the sequencing metrics, presenting 
data such as the number of reads obtained, the number of 
sequenced bases, and the target region coverage (%>10X, 
%>20X, and %>30X).
3.3 | Genetic analysis
An average of 500 nonreference alleles per patient were 
identified during the variant calling protocol. After apply-
ing the prioritization criteria, 35/102 patients (34%) had at 
least one candidate variant, with one patient having two 
candidate variants in two different genes (Tables 2, 3, and 
Table S2).
3.3.1 | Common MODY genes
Among a total of 34 patients with only one candidate vari-
ant, in 47% (16/34) of them, the change was identified in 
one of the genes most commonly associated with MODY 
(three in HNF4A, seven in GCK, one in HNF1A, and four 
in HNF1B). Only one variant was shared by two probands 
(GCK—c.952G > A/p.Gly318Arg).
Of these variants, three were novel (two in HNF4A/one in 
GCK) and 12 had been described previously. According to the 
F I G U R E  1  Flowchart of the study 
cohort selection. To select candidates for 
tNGS, we performed an initial genetic 
screening in 198 probands for 3 MODY 
subtypes, namely, GCK, HNF1A, and 
HNF1B. This candidate gene approach 
has been guided using clinical laboratory 
characteristics specific to each phenotype. 
Only 1 gene was investigated per patient, 
using Sanger sequencing (GCK OR 
HNF1A) OR MLPA (HNF1B). The cohort 
described in the current study is composed 
of patients who did not present any 
candidate variant in this initial approach 
(GCK, HNF1A, HNF1B) and were selected 
for tNGS. *Minimum inclusion criteria: 
Available in Supplemental Material - 
Cohort Selection and Data Analysis; ¥ 
Number of patients presenting pathogenic / 
likely pathogenic variants
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ACMG/AMP guidelines, 60% (9/15) were considered patho-
genic or likely pathogenic, 27% (4/15) of uncertain significance, 
and 13% (2/15) benign (already reported). A cosegregation 
analysis was possible in nine of the 16 families (Figure 2).
3.3.2 | Rare MODY genes
Eighteen patients (53% (18/34)) had only one candidate 
variant in genes that are rarely associated with MODY (two 
PDX1; one NEUROD1; four CEL; three INS; seven ABCC8; 
one KCNJ11), most of which (94% (17/18)) had an initial 
clinical suspicion of non‐GCK MODY. No variant was 
shared by two or more probands.
Five variants (28% (5/18)) were described for the first 
time in this study. The remainder (72% (13/18)) had been re-
ported in the literature and/or mapped in genomic databases 
(gnomAD/ABraOM). Only four (22% (4/18)) were classi-
fied as pathogenic by ACMG/AMP, three (17% (3/18)) were 
likely benign, and the majority (61% (11/18)) with uncertain 
significance.
Only one case (3%–1/35) presented candidate variants in 
two genes. In this patient, two novel missense changes of un-
certain significance were present in CEL and ABCC8.
Table 4 presents clinical follow‐up data and additional in-
formation for patients with pathogenic/probably pathogenic/
uncertain significance candidate variants in rare MODY 
genes. Six of the 19 families were available for cosegregation 
analysis (Figure 2).
4 |  DISCUSSION
The use of a genetic panel to investigate a multilocus disease 
with large associated genes (without hotspots), as in MODY, 
is extremely advantageous in relation to the gene‐specific ap-
proach by Sanger sequencing (Colclough et al., 2014; Ellard 
et al., 2013). In recent years, some cohorts of MODY patients 
have been investigated using gene panels (Alkorta‐Aranburu 
et al., 2014; Bonnefond et al., 2014; Ellard et al., 2013). 
However, these panels are not adequate for interrogating the 
genetic causes of MODY in many countries, such as Brazil, 
where the prevalence of MODY‐X (without genetic diagnosis) 
ranges from 46.2% to 73.9% (Furuzawa et al., 2008; Maraschin 
et al., 2008; Moises et al., 2001; Santana et al., 2017; Weinert 
et al., 2014). Thus, a thorough investigation of the rarer sub-
types of MODY is needed to improve their genetic diagnosis.
It is important to note that the study of rare MODY 
genes in a cohort preselected for the most common subtypes 
would contribute to the clarification of a minority of cases. 
A whole‐exome sequencing (WES) approach would be more 
efficient for clarifying not only rare MODY subtypes but also 
possible new genotype‐phenotype associations. In centers lo-
cated in emerging countries, however, the availability of fi-
nancial resources is still a limiting factor and gene‐candidate 
approaches are routinely used in the selection of cases for 
broad genomic studies, such as WES.
With this work, and with reference to a previous publi-
cation (Santana et al., 2017), our group set out to investigate 
all the most frequent genes associated with MODY using a 
genetic panel in a cohort of Brazilian families. After exclud-
ing all benign, likely benign, and uncertain significance vari-
ants, besides those pathogenic/probably pathogenic ones that 
presented, despite their ACMG/AMP classification, some 
uncertain characteristic as to their definitive phenotypic as-
sociation, we were able to assign a genetic cause for 12.7% 
(13/102) of the patients, consistent with the rate previously 
observed in similar studies (11%–33%) (Ellard et al., 2013; 
Pezzilli et al., 2018; Szopa et al., 2015).
Forty‐three percent of the candidate genetic findings 
(15/35), especially in rare MODY genes, were classified as 
variants of uncertain significance for having insufficient or 
conflicting evidence in the phenotypic association. Four of 
these variants of uncertain significance (4/15) have an allele 
T A B L E  1  Clinical and laboratory data for the cohort at the first 
evaluation
 
Median (1st | 3rd quartile)f or 
Percentageg
Age at diagnosis of diabe-
tes or MFHa (years)
20 (14 | 27.7)
Fasting plasma glucose 
(mg/dL)
131 (104 | 213)
A1C (%) 7.5 (6.0 | 9.2)
Glucose tolerance test 
(GTT) incrementb (mg/dL)
109 (102 | 115)
Fasting C‐peptidec (ng/mL) 1.7 (1.2 | 2.5)
Referred weight at 
diagnosisd
14%‐low | 70%‐normal | 13%‐over-
weight | 3%‐obesity
Family history of diabetes/
MFH
94%‐positive | 5%‐negative | 
1%‐unknown





Note: Normal range: Fasting plasma glucose (hexokinase) 70–99 mg/dL; A1C 
(HPLC) 4.1%–6.0%; Fasting C‐peptide (chemiluminescence) 1.1–4.4 ng/mL; 
Microalbuminuria (immunoturbidimetry) <14.0 mg/L; Glucose tolerance test 
(hexokinase) 0 min 70–99 mg/dL | 120 min < 140 mg/dL.
aMFH: mild fasting hyperglycemia. 
b2 hr glucose‐fasting glucose (25 patients screened). 
cFasting C‐peptide: 3 years after diagnosis. 
dReported by the patient (“referred weight”). 
eMicrovascular complications: Retinopathy (77 patients screened), 
Microalbuminuria (87 patients screened). 
fContinuous variables. 
gDiscrete variables. 
hOHA: oral hypoglycemic agent. 
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frequency equal to or greater than 1/15,000 in gnomAD: 
p.His505Asn (HNF1A), p.Gly76Cys (HNF1B), p.Arg6His 
(INS), and p.Val161Met (CEL), a frequency similar to the 
risk of type 2 diabetes alleles mapped in common MODY 
genes, such as HNF1A (Najmi et al., 2017). This observation 
would support the notion of a complex/polygenic context of 
hyperglycemia, making them benign in the face of our mono-
genic hypothesis. Even for those variants with a populational 
frequency lower than expected for MODY, we cannot rule out 
the possibility of a spurious finding, as observed in rare non-
synonymous changes mapped in individuals without diabetes 
(Flannick et al., 2013).
If we consider the extended genetic approach of our en-
tire cohort (combining the 2017 (Santana et al., 2017)/2019 
(Dotto et al., 2019) studies, the present one, and added 40 
MODY‐GCK/HNF1A unpublished cases (Table S3)), the 
overall positivity (pathogenic/likely pathogenic variants) 
would reach 50% (89/178), where 178 is the total number of 
cases already investigated by Sanger sequencing or MLPA 
and tNGS. As a consequence of this wider analytical ap-
proach, a more precise number of cases with MODY‐X can 
be obtained, reaching 50% (89/178), which is still higher 
than the average (currently 15%–20% (Chèvre et al., 1998; 
Fajans et al., 2001; Frayling et al., 2001; Frayling et al., 
2003; Shepherd, Sparkes, & Hattersley, 2001; Shields et 
al., 2010)) reported in the literature worldwide. This num-
ber, however, may be lower since some of these unclarified 
cases may harbor genetic defects that were not investigated 
in this study (copy number variations, CNVs/large indels) 
or were located in regulatory and intronic regions, such as 
in genes that have not yet been related to the phenotype. 
In addition, we cannot rule out the possibility of patients 
who were investigated due to initial suspicion of MODY but 
presented another type of Diabetes Mellitus (DM) (overlap-
ping clinical characteristics). Finally, the higher percentage 
of MODY‐X cases may be related to the genetically het-
erogeneous composition of our population, with centuries 
of colonization and immigration of people from dozens of 
countries, resulting in the observed mixing (Cardoso, de 
Oliveira, Paixão‐Côrtes, Castilla, & Schuler‐Faccini, 2019). 
This characteristic may have contributed, in some way, to 
the existence of a different set of MODY genes that are not 
found in European populations from which the current set of 
MODY genes have been identified. Thus, the use of multi-
loci genomic approaches (such as WES) could uncover new 
MODY gene–phenotype associations in this non‐European 
population.
Among patients with at least one candidate variant, 46% 
(16/35) presented with the nonreference allele in a common 
MODY gene. In five of them (31%–5/16), the same gene was 
previously analyzed by Sanger sequencing (Santana et al., 
2017) (GCK or HNF1A), with a negative result (missed het-
erozygote) (Table 2). As these five heterozygotes that Sanger 
sequencing missed are from our previous study (Santana et 
al., 2017), with 35 cases (i.e., 40 true heterozygous geno-
types), our missed heterozygote rate (MHR) reached 12.5% 
(5/40—uncalled heterozygotes/all heterozygous genotypes), 
consistent with the reported global MHR (9.1%–14.5%) 
(Quinlan & Marth, 2007).
In these patients, a false‐negative result occurred due 
to an allelic dropout or an analytic error. Allele dropout is 
a rare molecular event with an estimated occurrence rate 
of 0.3% (Blais et al., 2015). It has dependent and indepen-
dent allele causal factors and has been reported during ge-
netic research of numerous diseases (Fujimura, Northrup, 
Beaudet, & O’Brien, 1990; Lam & Mak, 2013; Schulze, 
Bettendorf, Maser‐gluth, Decker, & Schwabe, 1998; 
Somerville, Sprysak, Hicks, Elyas, & Vicen‐Wyhony, 
1999; Wenzel et al., 2009), including MODY (Ellard et al., 
1999; Raeder et al., 2006).
The three cases observed in our cohort (GCK‐5/p.
Gly318Arg; GCK‐6/p.Gly318Arg; GCK‐7/p.Thr326Pro) oc-
curred in exon 8 of the GCK. The allele was "lost" during 
PCR due to the variant rs76323047 present at the primer an-
nealing site (NGRL Manchester, 2019), and it was recovered 
after oligo modification. This finding highlights an import-
ant Sanger sequencing limitation that is overcome by new 
sequencing technologies.
The remaining 11 common MODY cases represent the 
restrictions of a single‐gene approach, in addition to the 
application of only one molecular investigation method 
(Sequencing or MLPA).
Among these patients, a number of notable findings are 
further detailed below.
4.1 | HNF4A | OMIM #125850
Of the three cases in which candidate variants were identi-
fied in HNF4A, only one comprised a previously described 
genetic finding (c.1321A  >  G/p.Ile441Val). The family 
reported by Malecki et al. (1999), however, had a geno-
type–phenotype discrepancy (unaffected bearer) in addition 
to cosegregation in half of the HNF4A variant bearers (as 
well as other affected family members), of a second vari-
ant (HNF1A—c.872dupC/p.Gly292Argfs*25—pathogenic). 
We must also point out that the HNF4A—c.1321A > G/p.
Ile441Val was mapped at a frequency higher (0.08%) than 
that expected for MODY in a local cohort of 609 healthy 
Brazilian elderly individuals (ABraOM) (Naslavsky et al., 
2017). All these findings resulted in a benign ACMG clas-
sification. Even with its isolated association with MODY 
is unproven, Malecki et al. (1999) noted that patients who 
carried both variants (HNF1A/HNF4A) presented an earlier 
age of diagnosis and the need for insulin therapy. Of the two 
remaining variants identified, neither had yet been described 
to be associated with the phenotype. However, one of them 
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T A B L E  3  Allelic candidate variants identified using a gene panel in MODY probands with a negative prior genetic analysis
Gene Nucleotide changea Aminoacid changea Region Proband (s) ACMGb Reference (first report)
HNF4A c.7A > G p.Ser3Gly Exon 1 HNF4A‐1 U.S This studyc
c.145C > T p.His49Tyr Exon 2 HNF4A‐2 U.S This study
c.1321A > G p.Ile441Val Exon 10 HNF4A‐3 B Malecki et al. (1999)
GCK c. 544G > A p.Val182Met Exon 5 GCK‐1 P Froguel et al. (1993)
c.554T > A p.Leu185Gln Exon 5 GCK‐2 L.P This study
c.622G > C p. Ala208Pro Exon 6 GCK‐3 L.P Garin et al. (2008)
c.703A > G p.Met235Val Exon 7 GCK‐4 P García‐Herrero et al. (2007)
c.952G > A p.Gly318Arg Exon 8 GCK‐5, 
GCK‐6
P Pruhova et al. (2003)
c.976A > C p.Thr326Pro Exon 8 GCK‐7 P Lorini et al. (2009)
c.1340_1368del29 p.ArgR447Lfs*2 Exon 10 GCK‐8 P Ziemssen, Bellanné‐
Chantelot, Osterhoff, 
Schatz, and Pfeiffer, (2002)
HNF1A c.1513C > A p.His505Asn Exon 8 HNF1A‐1 U.S Bellanne‐Chantelot et al. 
(2008)
PDX1 c.188delC p.Pro63Argfs*60 Exon 1 PDX1‐1 P Stoffers, Ferrer, Clarke, and 
Habener (1997)
c.664G > A p.Glu222Lys Exon 2 PDX1‐2 U.S This studyc
HNF1B c.182T > G p.Val61Gly Exon 1 HNF1B‐1 B Edghill, (2005)
c.226G > T p.Gly76Cys Exon 1 HNF1B‐2 U.S Bellanne‐Chantelot et al. 
(2005)
c.443C > T p.Ser148Leu Exon 2 HNF1B‐3 P Edghill (2005)
c.884G > A p.Arg295His Exon 4 HNF1B‐4 L.P Bellanné‐Chantelot et al. 
(2004)
NEUROD1 c.693C > G p.Tyr231Ter Exon 2 NEUROD1‐1 P This study
CEL c.71C > T p.Ala24Val Exon 1 CEL‐1 U.S This studyc
c.305A > C p.Asp102Ala Exon 3 CEL‐2 U.S This study
c.481G > A p.Val161Met Exon 4 CEL‐3 U.S This studyc
c.796A > G p.Lys266Glu Exon 7 D1 U.S This study
c.2152C > A p.Pro718Thr Exon 11 CEL‐4 L.B Johansen et al. (2014)
INS c.17G > A p.Arg6His Exon 1 INS‐1 U.S Meur et al. (2010)
c.65delC p.Ala23Glnfs*3 Exon 2 INS‐2 P This study
c.227G > A p.Ser76Asn Exon 3 INS‐3 L.B This studyc
ABCC8 c.157A > T p.Ser53Cys Exon 2 ABCC8‐1 U.S This study
c.703G > A p.Ala235Thr Exon 5 ABCC8‐2 L.B This studyc
c.1688T > A p.Val563Asp Exon 12 ABCC8‐3 U.S This study
c.1973G > T p.Gly658Val Exon 14 ABCC8‐4 U.S This studyc
c.2017G > A p.Asp673Asn Exon 14 ABCC8‐5 U.S This studyc
c.2473C > T p.Arg825Trp Exon 20 ABCC8‐6 P Vaxillaire et al. (2007)
c.3053C > T p.Ser1018Leu Exon 25 D1 U.S This studyc
c.3440T > G p.Leu1147Arg Exon 28 ABCC8‐7 U.S Gussinyer et al. (2008)
KCNJ11 c.286G > A p.Ala96Thr Exon 1 KCNJ11‐1 U.S Melikyan et al. (2012)
aRefSeq reference transcript: NM_175914.3 (HNF4A)/NM_000162.3 (GCK)/NM_000545.6 (HNF1A)/NM_000209.3 (PDX1)/NM_000458.2 (HNF1B)/NM_002500.3 
(NEUROD1)/NM_001807.3 (CEL)/NM_000207.2 (INS)/NM_000352.3 (ABCC8)/NM_000525.3 (KCNJ11). 
bACMG five‐tier system: B (Benign), L.B (Likely benign), P (Pathogenic), L.P (Likely pathogenic), U.S (Uncertain significance). 
cReported in The Genome Aggregation Database (gnomAD). 
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(c.A7G/p.Ser3Gly—uncertain significance) was mapped in 
a public genomic database (gnomAD) at an allele frequency 
lower (0.0004%) than expected for MODY. It is important 
to note that it was not possible to distinguish more typical 
MODY‐HNF4A characteristics, such as macrosomia, neo-
natal hypoglycemia (Pearson et al., 2007), or good sulfo-
nylurea response (Pearson et al., 2003), in either of the two 
patients.
F I G U R E  2  Pedigrees of screened MODY families with pathogenic/likely pathogenic/uncertain significance variants (A - Common MODY 
genes, B - Rare MODY genes). Square: male; Circle: female; Grey filled symbol: patient with prediabetes; Black filled symbol: patient with 
diabetes; Empty symbol: patient without diabetes nor prediabetes; Green filled symbol: renal cysts; Red filled symbol: pancreatic malformation; 
Blue filled symbol: low fecal elastase (LFE); Yellow filled symbol: LDL elevation; WT: wild-type allele; MT: altered allele; ?/?: patient not 
genotyped
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4.2 | GCK
Three patients with initial diagnostic suspicion of 
MODY‐HNF1A presented previously described patho-
genic/probably pathogenic variants in GCK. The diagnostic 
hypothesis error occurred due to the presence of an atypi-
cal glycemic pattern and/or a good therapeutic response to 
sulfonylurea (probands GCK‐1/GCK‐3/GCK‐4—Table 2). It 
is important to highlight that all of these patients currently 
control their glycemic levels by means of diet alone, demon-
strating the importance of a genetic diagnosis with the correct 
MODY subtype identification.
4.3 | HNF1B
Four probands were identified with candidate changes in 
HNF1B and to our surprise, only one had initial clinical 
manifestations specific to this MODY subtype (multiple 
renal cysts and pancreas body/tail agenesis). In one of the 
three remaining cases, the candidate variant c.182T > G/p.
Val61Gly, which had been previously described, was dis-
regarded at the end of its ACMG classification. Despite 
changes having been described in numerous cohorts 
(Bonnefond et al., 2014; Edghill, Bingham, Ellard, & 
Hattersley, 2006; Faguer et al., 2011; Granberg et al., 2012; 
Hoskins et al., 2007; Oram et al., 2010), in patients with 
DM and renal/pancreatic/genitourinary dysgenesis, a func-
tional study (Granberg et al., 2012) showed no difference 
in comparison between the variant and its wild‐type allele. 
In addition, it was mapped at a high frequency for MODY 
in both the global (gnomAD) and local Brazilian cohorts 
(ABraOM), contributing to benign ACMG categorization. 
Although the last two cases initially did not show evident 
pancreatic/extra pancreatic manifestations, a phenotypic 
correlation with the HNF1B genetic finding was established. 
The proband bearer of the described likely pathogenic vari-
ant c.884G > A/p.Arg295His was investigated, after genetic 
testing, for the presence of typical dysgenesis. Magnetic 
resonance imaging (MRI) demonstrated pancreas body/tail 
agenesis in addition to the presence of renal cysts. Despite 
this finding, the patient had normal renal/liver function in 
addition to normomagnesemia. Finally, in the bearer of 
the described uncertain significance variant c.226G > T/p.
Gly76Cys, a pancreas diffuse volume reduction was found 
after performing a CT scan. Additionally, an elevation of 
hepatic enzymes was observed without apparent functional 
impairment.
It is important to highlight how the use of a gene panel was 
a decisive factor for the correct identification of the MODY 
subtype in these cases. The genetic diagnoses of these pa-
tients could have been missed due to the absence of typical 
clinical findings during the first evaluation. In addition, be-
cause large deletions are a frequent finding in MODY‐HNF1B 
(in approximately 50% or more of the cases) (Edghill et al., 
2013), the initial approach aimed to identify CNVs in the 
gene. Our three cases presented missense variants.
Over half (53% (18/34)) of the cases identified with only 
one candidate variant showed a change in a rare MODY gene, 
evidencing the importance of the investigating rare MODY 
subtypes.
4.4 | PDX1 | OMIM #606392
In addition to the family with a new phenotype already 
described by our group (Caetano et al., 2018), a second 
proband was identified with the uncertain significance vari-
ant c.664G  >  A/p.Glu222Lys. Its population frequency, 
however, was high in the local control cohort (ABraOM), 
contributing to its ACMG classification. A familial coseg-
regation analysis, in addition to an investigation of possible 
pancreatic malformations (Caetano et al., 2018), will help to 
determine the pathogenicity of the variant.
4.5 | NEUROD1 | OMIM #606394
The only nonsense modification in the cohort, the novel 
pathogenic c.693C  >  G/p.Tyr231Ter, was present in 
NEUROD1. Heterozygous variants in this gene are a rare 
cause of MODY, with a notable incomplete penetrance 
among the members of reported families (Demirbilek et al., 
2018). Extrapancreatic manifestations have already been 
described, such as neurological abnormalities in homozy-
gous individuals (permanent neonatal diabetes mellitus) 
(Demirbilek et al., 2018; Rubio‐Cabezas et al., 2010). Our 
patients did not present any other atypical clinical findings, 
besides the classic MODY remarks. Cosegregation analy-
sis could help to reinforce the final interpretation of this 
variant, which compromises the NEUROD1 transactiva-
tion domain (Rubio‐Cabezas et al., 2010).
4.6 | CEL | OMIM #609812
CEL was the second, among rare MODY genes, with the 
largest number of candidate variants: five with uncertain 
significance missense changes. None of them had been 
previously described to be associated with the phenotype, 
and one was identified in one case with another candidate 
variant (ABCC8). Approximately, half of these CEL vari-
ants were mapped in the gnomAD consortium at an allele 
frequency lower than expected for MODY, which would 
not initially discard them from a probable association with 
the phenotype. The CEL analysis by first/second‐generation 
sequencing constituted a challenge due to its structure. The 
presence of its in‐tandem pseudogene (CELP) (Madeyski, 
Lidberg, Bjursell, & Nilsson, 1998) hindered the precise read 
alignment and variant calling process. In addition, it was 
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extremely polymorphic and had a variable number of tandem 
repetitions (VNTR) in exon 11. Segments of approximately 
33 bp may be repeated 7–23 times in the general population 
(Torsvik et al., 2010). Until now, only frameshift mutational 
events in this region were associated with a monogenic dia-
betes‐pancreatic exocrine dysfunction syndrome with typical 
fecal elastase deficiency (FED), mild abdominal pain, and 
loose stools (Ræder et al., 2006; Torsvik et al., 2010). All 
five candidate variants identified in our cohort were mis-
sense, and only one was located in exon 11. In addition, none 
of the patients showed any clinical signs of exocrine pan-
creatic deficiency. However, one of the CEL‐2 relatives had 
low fecal elastase. The proband of this family also showed 
a reduction in the volume of the pancreas on the MRI and 
microalbuminuria. Interestingly, three patients (variants in 
exons 1, 3, and 11) showed Low‐density lipoprotein eleva-
tions, one of which was diagnosed with aortic atheromatosis. 
A fraction of the CEL lipase has already been detected in the 
plasma, suggesting its interaction with cholesterol molecules 
and lipoproteins (Bengtsson‐Ellmark et al., 2004; Caillol et 
al., 1997). Although these variants may influence the lipid 
profile of these patients, their definitive association with 
MODY could not yet be established in our cohort. An ex-
tension of cosegregation analysis in these families, with the 
exception of that already performed with the CEL‐2 proband, 
would help to determine the degree of pathogenicity of these 
variants.
4.7 | INS | OMIM #613370
With the exception of the probably benign and uncertain 
significance INS variants, only one (1/3) was classified 
as pathogenic according to ACMG/AMP guidelines. The 
novel heterozygous frameshift c.65delC/p.Ala23Glnfs*3 
truncates the protein in preproinsulin signal peptide (Liu 
et al., 2015). Different molecular mechanisms (and inherit-
ance models) have been previously described for the phe-
notypes caused by INS variants, that is, processing defects 
in preproinsulin, proinsulin misfolding, ER stress, and 
impaired insulin binding to its receptor (Liu et al., 2015). 
Since the INS does not suffer from haploinsufficiency, as 
previously demonstrated experimentally using knockout 
mice (Leroux et al., 2001), the molecular pathogenesis re-
lated to the dominant inheritance model is attributed to the 
mutated protein cytotoxicity (Oyadomari et al., 2002; Ron, 
2002; Wang et al., 1999), rather than insulin deficiency 
(recessive inheritance) (Garin et al., 2010; Raile et al., 
2011). Our variant c.65delC/p.Ala23Glnfs*3 is predicted 
to undergo nonsense‐mediated decay (NMD) due to the 
premature termination codon (PTC) at amino acid position 
26. Thus, no protein would be generated and there is no 
toxic gain of function effect. Among the dominant‐inherit-
ance INS variants already reported, there is only one null 
type: a heterozygous de novo stop‐gain p.Tyr108Ter. The 
variant was identified in a permanent neonatal diabetes pa-
tient (Colombo et al., 2008). Functional evidence suggests 
that the truncated protein is translated, and NMD is not 
involved, leading to a proinsulin misfolding with ER stress, 
in addition to improper disulfide bonds with little or no 
insulin secretion. In this case, an NMD escaping was pos-
sible due to PTC position (within the last exon of a gene) 
(Kurosaki & Maquat, 2016; Nagy & Maquat, 1998). This 
would apply to any PTC occurring at amino acid position 
43 onwards in the INS. Despite the ACMG/AMP classifi-
cation, so far, there is no functional evidence to suggest 
that c.65delC/p.Ala23Glnfs*3 will escape NMD. Hence, 
the role of this INS variant in heterozygous state in diabetes 
phenotype remains to be determined.
4.8 | ABCC8 | OMIM *600509
ABCC8 had the largest number of candidate changes, with 
eight in total, among which one was in a patient with another 
candidate variant (CEL). Only one of the eight ABCC8 vari-
ants could be classified as pathogenic, the missense variant 
p.Arg825Trp/p.R825W, which was previously associated 
with MODY in a French subject (Riveline et al., 2012), in a 
study demonstrating the impairment of its function (de Wet 
et al., 2008), and which almost completely segregated with 
the phenotype in our family. The only observed genotype/
phenotype discrepancy was most likely due to incomplete 
penetrance, as already described (Klupa et al., 2009). It is 
important to note that the proband was diabetic for more 
than 30 years and always controlled his hyperglycemia with 
low doses of sulfonylurea. This good therapeutic response 
is classically observed in neonatal diabetes cases due to 
sulfonylurea receptor 1 (SUR1) (encoded by ABCC8) path-
ogenic variants (Rafiq et al., 2008). Finally, an atypical find-
ing caught our attention. The ABCC8‐7 proband, a typical 
initial suspicion of MODY‐HNF1B (multiple bilateral renal 
cysts associated with DM), presented an already described 
uncertain significance variant in ABCC8. Curiously, the 
change p.Leu1147Arg/p.L1147R was reported in compound 
heterozygosity associated with neonatal diabetes (OMIM 
#606176) (Alkorta‐Aranburu et al., 2014) and persistent 
hyperinsulinemic hypoglycemia of infancy (PHHI) (OMIM 
#256450) (evolving to glucose intolerance) (Gussinyer et 
al., 2008). Our patient did not present any typical neonatal 
characteristics of the previously mentioned phenotypes. We 
believe that cosegregation analysis could help to clarify the 
role of this heterozygosis variant in this family. It should 
be noted, however, that great clinical heterogeneity has al-
ready been described with ABCC8 variants, in the most di-
verse forms of inheritance (Klupa et al., 2009). In addition, 
the presence of renal cysts may only be an incidental finding 
unrelated to DM.
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4.9 | KCNJ11 | OMIM #616329
The only KCNJ11 candidate variant p.Ala96Thr was classi-
fied as uncertain significance and reported twice, namely, in 
homozygosis (Melikyan et al., 2012) and in an apparent focal 
case (somatic loss of heterozygosity (LOH)) (Mohnike et al., 
2014) associated with congenital hyperinsulinism. A detailed 
clinical report about relative carriers is not available. A het-
erozygous father was cited in the focal case study; however, 
hyperglycemia was not mentioned (only congenital hyperinsu-
linism discarded). In our family, six members were screened. 
Genotype–phenotype discrepancy was observed in one individ-
ual. The unaffected proband's granddaughter carried the variant 
without any glycemic alteration. As with ABCC8, also a subunit 
encoder of the pancreatic beta‐cell ATP‐sensitive channel, di-
verse phenotypes with distinct inheritance patterns have been 
previously associated with KCNJ11 (neonatal diabetes | OMIM 
#606176 (Gloyn et al., 2004), MODY (Bonnefond et al., 
2012), and hyperinsulinemic hypoglycemia | OMIM #601820 
(Thomas, Ye, & Lightner, 1996)). This genetic‐molecular spec-
trum often hinders the interpretation of mono/biallelic carriers, 
as in the KCNJ11 p.Arg34Cys variant and transient neonatal 
diabetes/congenital hyperinsulinism, which is subsequently 
clarified using expression studies (Snider et al., 2013).
5 |  CONCLUSIONS
The gene panel used in this study allowed for the simultane-
ous analysis of 11 genes frequently associated with MODY for 
the first time in a Brazilian cohort of genetically unclarified 
cases. This approach allowed for the detection of variants in 
genes not usually studied for the genetic diagnosis of MODY 
at most Brazilian medical centers, contributing to the identi-
fication of rare subtypes. As a result, the large percentage of 
local "MODY-X" cases commonly reported was reduced.
The identification of rare MODY subtypes is important to 
expand on existing reports. Given the small number of sub-
jects and the often‐great phenotypic variability (even intra-
family), establishing a typical clinical laboratory pattern, in 
contrast to the established effects of the most prevalent ones, 
is challenging.
Therefore, the use of multiloci genomic approaches (such 
as targeted sequencing or WES) is of fundamental importance, 
allowing for the genetic diagnosis of typical unclarified cases. 
Moreover, it allows for a better clinical, therapeutic, and prog-
nostic characterization of rare phenotypes, thus contributing to 
our understanding of the basic pathogenesis of common diseases.
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